Compare Figs Inc (FIGS) vs McKesson Corporation (MCK) Price & Performance

FIGS stock trades at $14.98, up 6.24% today, with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, with 2025 revenue reaching $631.10M and net income of $34.25M. Recent earnings beats and raised 2026 guidance signal operational strength, though valuation multiples remain elevated with a P/E of 42.61. International expansion continues to drive growth, with Q2 international sales surging 67%.

The outlook remains positive with analyst consensus pointing to 26.4% upside potential to $18.00 target. Strong fundamentals and momentum are balanced by rich valuation requiring continued execution. Key risks include premium pricing pressure and competitive threats in healthcare apparel. Wall Street sentiment leans bullish with 60% buy ratings among 15 analysts covering the stock.

McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.

Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.